Did you mean melanoma ii?
Displaying drugs 626 - 650 of 714 in total
Brasofensine
Brasofensine is an orally administered dopamine reuptake inhibitor being developed for the treatment of Parkinson's Disease. Phase I/II trials for brasofensine have been completed in the U.K. In November 2001, NeuroSearch confirmed that the drug's development was discontinued in favor of NS 2230.
Investigational
Matched Description: … Phase I/II trials for brasofensine have been completed in the U.K. …
4'-Methylene-5,8,10-trideazaaminopterin
CH-1504 is a an antirheumatic agent that has been shown in vitro to be a nonpolyglutamylatable and nonhydroxylatable antifolate that is more efficiently taken up into cells by the reduced folate carrier (RFC) system than is Methotrexate. It has been investigated for the treatment of Rheumatoid Arthritis (phase II).
Investigational
Matched Description: … It has been investigated for the treatment of Rheumatoid Arthritis (phase II). …
Iron polymaltose
Experimental
Docaravimab
Investigational
Lucanthone
One of the schistosomicides, it has been replaced largely by hycanthone and more recently praziquantel. (From Martindale The Extrapharmacopoeia, 30th ed., p46). It is currently being tested as a radiation sensitizer.
Investigational
Bezitramide
Bezitramide is a narcotic analgesic which was discovered in 1961, clinically tested around the 1970's , and marketed under the name Burgodin. After cases of fatal overdose in the Netherlands in 2004 the drug was withdrawn from the market.
Bezitramide has never been FDA approved and is currently a schedule...
Experimental
Illicit
Withdrawn
Matched Description: … Bezitramide has never been FDA approved and is currently a schedule II drug. …
Flupirtine
Flupirtine is a pyridine derivative that is in clinical use as a nonopioid analgesic. It was approved for the treatment of pain in 1984 in Europe. It is not approved for use in the U.S. or Canada, but is currently in phase II trials for the treatment of fibromyalgia.
Investigational
Matched Description: … It is not approved for use in the U.S. or Canada, but is currently in phase II trials for the treatment …
VL-2397
Investigational
CCX915
CCX915 is developed by ChemoCentryx which targets the chemokine receptor CCR2 and is in phase 1 of clinical trial for the treatment of Multiple Sclerosis and Neurologic Disorders. The CCR2 receptor is thought to be of central importance to inflammatory diseases, such as multiple sclerosis (MS), Type II diabetes and...
Investigational
Matched Description: … thought to be of central importance to inflammatory diseases, such as multiple sclerosis (MS), Type II …
ZEN-012
ZEN-012 is a novel small molecule and the first anti-cancer drug in development involving two mechanisms of action: tubulin and topoisomerase II inhibition. ZEN-012 also expresses additional modes of action such as pro-apoptotic and anti-angiogenic properties. It is developed for the treatment of solid tumors.
Investigational
Matched Description: … first anti-cancer drug in development involving two mechanisms of action: tubulin and topoisomerase II …
Ethylmorphine
A narcotic analgesic and antitussive. It is metabolized in the liver by ethylmorphine-N-demethylase and used as an indicator of liver function. It is not marketed in the US but is approved for use in various countries around the world. In the US it is a schedule II drug (single-entity) and...
Experimental
Illicit
Matched Description: … In the US it is a schedule II drug (single-entity) and schedule III drug (in combination products). …
Recombinant Bacterial ACE2 Receptors-like Enzyme
B38-CAP is structured as a carboxypeptidase and derived from Paenibacillus sp. The molecule, an Angiotensin Converting Enzyme 2 (ACE2)-like enzyme, shares structural similarities to the mammalian ACE2. B38-CAP is an ACE2-like enzyme which decreases angiotensin II levels. It is being investigated for treating hypertension, myocardial fibrosis, and cardiac dysfunction.
Investigational
Matched Description: … B38-CAP is an ACE2-like enzyme which decreases angiotensin II levels. …
Genistein
An isoflavonoid derived from soy products. It inhibits protein-tyrosine kinase and topoisomerase-II (DNA topoisomerases, type II) activity and is used as an antineoplastic and antitumor agent. Experimentally, it has been shown to induce G2 phase arrest in human and murine cell lines.
Additionally, genistein has antihelmintic activity. It has been...
Investigational
Matched Description: … It inhibits protein-tyrosine kinase and topoisomerase-II (DNA topoisomerases, type II) activity and is …
Olcegepant
Boehringer Ingelheim Pharmaceuticals’ olcegepant (BIBN 4096) is a selective Calcitonin Gene-Related Peptide (CGRP) antagonist, a new class of drugs in development for the treatment of acute migraine attacks. Olcegepant is undergoing phase II trials in Europe and the US, with preliminary results suggesting that CGRP antagonists may represent a potential...
Investigational
Matched Description: … Olcegepant is undergoing phase II trials in Europe and the US, with preliminary results suggesting that …
SGN-30
SGN-30 is an engineered monoclonal antibody (mAb) that reacts with significant affinity to the CD30 antigen, which is highly expressed on a variety of hematologic malignancies as compared to on normal cells. SGN-30 has been shown to induce direct anti-cancer activity towards tumor cells expressing CD30 and is undergoing phase...
Investigational
Matched Description: … SGN-30 has demonstrated objective antitumor responses as a single agent in phase II clinical trials. ... shown to induce direct anti-cancer activity towards tumor cells expressing CD30 and is undergoing phase II …
WL-1002
WL-1002 is developed by Winston Laboratories which is a topical cream formulation of 075% zucapaicin (also known as civamide), for the treatment of pain due to osteoarthritis.
Investigational
RTA 744
RTA 744 is a novel anthracycline derivative that crosses the blood-brain barrier and shows significant potential for the treatment of primary and metastatic brain cancers. Anthracyclines are one of the most broadly used and effective classes of cancer therapies; however, they are not used to treat brain cancers because current...
Investigational
IT-139
Investigational
Flumequine
Flumequine is a synthetic chemotherapeutic antibiotic of the fluoroquinolone drug class used to treat bacterial infections.
Withdrawn
Matched Categories: … Topoisomerase II Inhibitors …
Pazufloxacin
Pazufloxacin is under investigation in clinical trial NCT02592096 (Pazufloxacin Mesilate Ear Drops Clinical Trial Protocol).
Investigational
Matched Categories: … Topoisomerase II Inhibitors …
IDM-4
IDM-4 is an immuno-designed molecule that completed phase I/II of investigation for the treatment of Leukemia. It is a monoclonal antibody-specific antigen that can selectively target cancer-affected cells by coupling with tumor cell-killing MAK cells, which are derived from the patient's own monocytes. Trials of this drug have most likely...
Investigational
Matched Description: … IDM-4 is an immuno-designed molecule that completed phase I/II of investigation for the treatment of …
Displaying drugs 626 - 650 of 714 in total